RTW

Latest Updates of Viva Biotech's Portfolio Companies

Retrieved on: 
Wednesday, March 6, 2024

NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs). Recently they announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy. AL01211 is a potent, oral, glucosylceramide synthase (GCS) inhibitor being developed for the treatment of Fabry disease and Type 1 Gaucher disease.

Key Points: 
  • This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
  • Recently, Viva Biotech's portfolio companies have new updates.
  • NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs).
  • Previously, the company had completed a $5.4 million seed funding round, with investors including Rev1 Ventures, Broadview Ventures, and Viva Biotech.

RTW Charitable Foundation Announces Six Research Grant Recipients

Retrieved on: 
Monday, February 12, 2024

RTW Charitable Foundation (“RTWCF”) announced today that it has awarded $900,000 in research grants to support six research studies.

Key Points: 
  • RTW Charitable Foundation (“RTWCF”) announced today that it has awarded $900,000 in research grants to support six research studies.
  • “Optimizing AAV-SPL gene therapy for sphingosine phosphate lyase insufficiency syndrome” (Julie Saba, University of California, San Francisco, San Francisco, CA).
  • “RTW Charitable Foundation is proud to provide financial and scientific support to these six incredible researchers and their respective studies.
  • In addition to delivering financial resources, RTWCF also provides grant recipients with hands-on scientific support, helping them improve or further develop their research and research tools and identify new therapeutic targets.

Scheme Effective

Retrieved on: 
Monday, February 12, 2024

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.

Key Points: 
  • This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.
  • This announcement is not an offer of securities for sale into the United States.
  • The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.
  • RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.

Suspension of Trading in Shares

Retrieved on: 
Monday, February 12, 2024

The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.

Key Points: 
  • The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.
  • Consideration Shares will be offered and sold outside of the United States to investors that are not U.S.
  • The transferability of the Consideration Shares will be further restricted by the terms of the AI/QP Investor Letter, and any re-offer or resale of any Consideration Shares in the United States or to U.S.
  • RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.

Transaction Update

Retrieved on: 
Wednesday, February 7, 2024

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.

Key Points: 
  • This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.
  • The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.
  • Consideration Shares will be offered and sold outside of the United States to investors that are not U.S.
  • RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.

Basking Biosciences Announces Close of $55 Million Financing to Accelerate Clinical Development for First Reversible Thrombolytic for Ischemic Stroke

Retrieved on: 
Thursday, February 1, 2024

Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy to treat stroke, today announced the close of a $55 million financing.

Key Points: 
  • Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy to treat stroke, today announced the close of a $55 million financing.
  • Steven Gillis, Ph.D., Managing Director of ARCH Venture Partners will serve as Chairman of Basking’s Board of Directors .
  • Basking will utilize the proceeds to accelerate clinical development of BB-031, a first-in-class, reversible RNA aptamer targeting von Willebrand Factor (vWF), engineered for rapid onset and short duration of effect.
  • Basking will initiate a Phase 2 proof-of-concept trial, the RAISE trial, in patients with acute ischemic stroke (AIS) in 2024.

Update on the Scheme and Publication of Notice of Second General Meeting

Retrieved on: 
Tuesday, January 30, 2024

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.

Key Points: 
  • This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.
  • The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.
  • RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.
  • If the Second General Meeting is adjourned, the Voting Record Time for the adjourned meeting will be 6.30 p.m. on the date two calendar days before the date set for the adjourned meeting.

Results of First General Meeting

Retrieved on: 
Tuesday, January 30, 2024

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.

Key Points: 
  • This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.
  • This announcement is not an offer of securities for sale into the United States.
  • The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.
  • RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.

Update on the Scheme and Resignation of Directors

Retrieved on: 
Tuesday, January 30, 2024

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.

Key Points: 
  • This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.
  • This announcement is not an offer of securities for sale into the United States.
  • The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.
  • RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.

Establishment Labs Announces $50 Million Private Placement and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2023

Retrieved on: 
Tuesday, January 9, 2024

The Company also announced preliminary unaudited financial results for the fourth quarter and fiscal year 2023.

Key Points: 
  • The Company also announced preliminary unaudited financial results for the fourth quarter and fiscal year 2023.
  • Preliminary unaudited revenue for the fourth quarter of 2023 is expected to be in the range of $31.4 million to $31.8 million, in line with the guidance provided on November 7 in the third quarter earnings release.
  • Based on the expected range for fourth quarter preliminary unaudited revenue, Establishment Labs expects full-year 2023 revenue of $165.0 million to $165.4 million.
  • Establishment Labs expects to use net proceeds from the private placement for working capital and other general corporate purposes.